Meinig G, Deisenroth K
Department of Neurosurgery and Neurotraumatology, Berufsgenossenschaftliche Unfallklinik, Frankfurt, Federal Republic of Germany.
Adv Neurol. 1990;52:295-300.
A dose-response relation was established for the antiedematous effect of dexamethasone in the rat brain, using the model of cold lesion-induced brain edema. Four doses corresponding to a human dose of 20 mg, 100 mg, 500 mg, and 2,500 mg dexamethasone (Fortecortin, E. Merck, Darmstadt, Germany) resulted in a highly significant edema reduction by 25%, 30%, and 50%, respectively, although the megadose of 2,500 mg showed less effect, only 30% reduction. Reproducible conditions with regard to animal material and sophisticated method used, exact analysis, manufacture and stability of the test substance dexamethasone, and scatter-reducing techniques and calculation procedures were the prerequisites for the clear result of the study. These results with the optimal dose of 500 mg dexamethasone obtained confirm recent therapy concepts in antiedematous therapy with ultra-high doses of dexamethasone in head injury. Carefully designed clinical studies on the subject of head injury and glucocorticoids may therefore be considered as extremely promising.
使用冷损伤诱导的脑水肿模型,建立了地塞米松对大鼠脑抗水肿作用的剂量反应关系。对应于人用剂量20毫克、100毫克、500毫克和2500毫克地塞米松(福皮质醇,德国达姆施塔特默克公司)的四个剂量,分别使水肿显著减少25%、30%和50%,尽管2500毫克的超大剂量效果较差,仅减少30%。关于动物材料和所用复杂方法的可重现条件、测试物质地塞米松的精确分析、制造和稳定性,以及减少散点的技术和计算程序是该研究获得明确结果的前提条件。所获得的地塞米松最佳剂量500毫克的这些结果证实了近期在颅脑损伤中超高剂量地塞米松抗水肿治疗的治疗理念。因此,关于颅脑损伤和糖皮质激素主题的精心设计的临床研究可能被认为极具前景。